Targeting PI3K in cancer: Any good news?

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Martini, Miriam ^a   Ciraolo, Elisa ^a   Gulluni, Federico ^a   Hirsch, Emilio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer; Class II phosphatidylinositol 3 kinase; Genetic determinants; PI3K; Therapeutics

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1, 3, 4, 7, 10, 11, 12, 13, 14, 15, 16, 17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10, 13 DIMETHYL 3, 7, 17 TRIOXO 2 OXACYCLOPENTA [A] PHENANTHREN 11 YL ACETATE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BUPARLISIB; COPANLISIB; DACTOLISIB; DOCETAXEL; DUVELISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GDC 0032; GEFITINIB; GSK2636771; IDELALISIB; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PICTILISIB; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; WORTMANNIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ASTHENIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TARGETING; DYSGEUSIA; ENDOMETRIUM CANCER; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOBLASTOMA; GLUCOSE HOMEOSTASIS; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MOOD DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; T WAVE INVERSION; THROMBOCYTOPENIA;

EID: 84889087725     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00108     Document Type: Review

References (95)

1. Antonescu, C. R. (2011). The GIST paradigm: lessons for other kinase-driven cancers. J. Pathol. 223, 251-261.
2. Arcaro, A., Khanzada, U. K., Vanhaesebroeck, B., Tetley, T. D., Waterfield, M. D., and Seckl, M. J. (2002). Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J. 21, 5097-5108.
3. Arcaro, A., Zvelebil, M. J., Wallasch, C., Ullrich, A., Waterfield, M. D., and Domin, J. (2000). Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol. Cell. Biol. 20, 3817-3830.
4. Arkenau, H.-T., Jones, S. F., Kurkjian, C., Infante, J. R., Pant, S., Burris, H. A., et al. (2012). The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. J. Clin. Oncol. 30, abstr. 3097. [ASCO Annual Meeting Proceedings].
5. Bendell, J. C., Rodon, J., Burris, H. A., De Jonge, M., Verweij, J., Birle, D., et al. (2012). Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290.
6. Bilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C., et al. (2006). Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107, 642-650.
7. Billottet, C., Grandage, V. L., Gale, R. E., Quattropani, A., Rommel, C., Vanhaesebroeck, B., et al. (2006). A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648-6659.
8. Brachmann, S. M., Kleylein-Sohn, J., Gaulis, S., Kauffmann, A., Blommers, M. J., Kazic-Legueux, M., et al. (2012). Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 11, 1747-1757.
9. Brown, R. A., Domin, J., Arcaro, A., Waterfield, M. D., and Shepherd, P. R. (1999). Insulin activates the alpha isoform of class II phosphoinositide 3-kinase. J. Biol. Chem. 274, 14529-14532.
10. Brunner-Kubath, C., Shabbir, W., Saferding, V., Wagner, R., Singer, C. F., Valent, P., et al. (2011). The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res. Treat. 129, 387-400.
11. Call, R., Grimsley, M., Cadwallader, L., Cialone, L., Hill, M., Hreish, V., et al. (2010). Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad. Med. 122, 158-165.
12. Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
13. Carden, C. P., Sarker, D., Postel-Vinay, S., Yap, T. A., Attard, G., Banerji, U., et al. (2010). Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov. Today 15, 88-97.
14. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074.
15. Cerniglia, G. J., Karar, J., Tyagi, S., Christofidou-Solomidou, M., Rengan, R., Koumenis, C., et al. (2012). Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol. Pharmacol. 82, 1230-1240.
16. Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., MacArulla, T., et al. (2010). Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 120, 2858-2866.
17. Diouf, B., Cheng, Q., Krynetskaia, N. F., Yang, W., Cheok, M., Pei, D., et al. (2011). Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298-1303.
18. Domin, J., Pages, F., Volinia, S., Rittenhouse, S. E., Zvelebil, M. J., Stein, R. C., et al. (1997). Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 326(Pt 1), 139-147.
19. Dong, H., Luo, L., Hong, S., Siu, H., Xiao, Y., Jin, L., et al. (2010). Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. BMC Syst. Biol. 4:163. doi:10.1186/1752-0509-4-163
20. Elis, W., Triantafellow, E., Wolters, N. M., Sian, K. R., Caponigro, G., Borawski, J., et al. (2008). Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death. Mol. Cancer Res. 6, 614-623.
21. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356.
22. Falasca, M., Hughes, W. E., Dominguez, V., Sala, G., Fostira, F., Fang, M. Q., et al. (2007). The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J. Biol. Chem. 282, 28226-28236.
23. Falasca, M., and Maffucci, T. (2007). Role of class II phosphoinositide 3-kinase in cell signalling. Biochem. Soc. Trans. 35, 211-214.
24. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
25. Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., et al. (2008). The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522-5532.
26. Fruman, D. A., and Rommel, C. (2011). PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 1, 562-572.
27. Gaidarov, I., Smith, M. E., Domin, J., and Keen, J. H. (2001). The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell 7, 443-449.
28. Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., et al. (2009). Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16, 115-125.
29. Harada, T., Chelala, C., Bhakta, V., Chaplin, T., Caulee, K., Baril, P., et al. (2008). Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27, 1951-1960.
30. Hollander, M. C., Blumenthal, G. M., and Dennis, P. A. (2011). PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11, 289-301.
31. Ihle, N. T., Lemos, R. Jr., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., et al. (2009). Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69, 143-150.
32. Iorns, E., Lord, C. J., and Ashworth, A. (2009). Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem. J. 417, 361-370.
33. Janku, F., Lee, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., et al. (2011a). PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 6:e22769. doi:10.1371/journal.pone.0022769
34. Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., et al. (2011b). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 10, 558-565.
35. Janku, F., Wheler, J. J., Naing, A., Stepanek, V. M., Falchook, G. S., Fu, S., et al. (2012). PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3, 1566-1575.
36. Janne, P. A., Gray, N., and Settleman, J. (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709-723.
37. Jou, S. T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J. R., Carpino, N., et al. (2002). Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580-8591.
38. Kim, J. S., Yun, H. S., Um, H. D., Park, J. K., Lee, K. H., Kang, C. M., et al. (2012). Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biol. Ther. 13, 1307-1318.
39. Knobbe, C. B., and Reifenberger, G. (2003). Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507-518.
40. Kok, K., Geering, B., and Vanhaesebroeck, B. (2009). Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 34, 115-127.
41. Koul, D., Fu, J., Shen, R., Lafortune, T. A., Wang, S., Tiao, N., et al. (2012). Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 18, 184-195.
42. Koutros, S., Schumacher, F. R., Hayes, R. B., Ma, J., Huang, W. Y., Albanes, D., et al. (2010). Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res. 70, 2389-2396.
43. Krop, I. E., Saura, C., Ahnert, J. R., Becerra, C., Britten, C. D., Isakoff, S. J., et al. (2012). A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. J. Clin. Oncol. 30, abstr. 508. [ASCO Annual Meeting Proceedings].
44. Ktori, C., Shepherd, P. R., and O'Rourke, L. (2003). TNF-alpha and leptin activate the alpha-isoform of class II phosphoinositide 3-kinase. Biochem. Biophys. Res. Commun. 306, 139-143.
45. Lambros, M. B., Fiegler, H., Jones, A., Gorman, P., Roylance, R. R., Carter, N. P., et al. (2005). Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J. Pathol. 205, 29-40.
46. Lannutti, B. J., Meadows, S. A., Herman, S. E., Kashishian, A., Steiner, B., Johnson, A. J., et al. (2011). CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591-594.
47. Laplante, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell 149, 274-293.
48. Liu, P., Cheng, H., Roberts, T. M., and Zhao, J. J. (2009a). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644.
49. Liu, T. J., Koul, D., Lafortune, T., Tiao, N., Shen, R. J., Maira, S. M., et al. (2009b). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 8, 2204-2210.
50. Liu, P., Morrison, C., Wang, L., Xiong, D., Vedell, P., Cui, P., et al. (2012). Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33, 1270-1276.
51. Liu, Z., Sun, C., Zhang, Y., Ji, Z., and Yang, G. (2011). Phosphatidylinositol 3-kinase-C2beta inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma. J. Int. Med. Res. 39, 1319-1332.
52. Low, S., Vougioukas, V. I., Hielscher, T., Schmidt, U., Unterberg, A., and Halatsch, M. E. (2008). Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib. Anticancer Res. 28, 3729-3732.
53. Maffucci, T., Cooke, F. T., Foster, F. M., Traer, C. J., Fry, M. J., and Falasca, M. (2005). Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J. Cell Biol. 169, 789-799.
54. Manara, M. C., Nicoletti, G., Zambelli, D., Ventura, S., Guerzoni, C., Landuzzi, L., et al. (2010). NVP-BEZ235 as a new therapeutic option for sarcomas. Clin. Cancer Res. 16, 530-540.
55. Martelli, A. M., Nyakern, M., Tabellini, G., Bortul, R., Tazzari, P. L., Evangelisti, C., et al. (2006). Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20, 911-928.
56. Martini, M., Vecchione, L., Siena, S., Tejpar, S., and Bardelli, A. (2012). Targeted therapies: how personal should we go? Nat. Rev. Clin. Oncol. 9, 87-97.
57. Miled, N., Yan, Y., Hon, W. C., Perisic, O., Zvelebil, M., Inbar, Y., et al. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242.
58. Moreno Garcia, V., Baird, R. D., Shah, K. J., Basu, B., Tunariu, N., Blanco, M., et al. (2011). A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J. Clin. Oncol. 29, 3021. [ASCO Annual Meeting Proceedings].
59. Moroney, J. W., Schlumbrecht, M. P., Helgason, T., Coleman, R. L., Moulder, S., Naing, A., et al. (2011). A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin. Cancer Res. 17, 6840-6846.
60. Mukherjee, B., Tomimatsu, N., Amancherla, K., Camacho, C. V., Pichamoorthy, N., and Burma, S. (2012). The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses. Neoplasia 14, 34-43.
61. Nanni, P., Nicoletti, G., Palladini, A., Croci, S., Murgo, A., Ianzano, M. L., et al. (2012). Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/-mice and treatment with PI3K inhibitor. PLoS ONE 7:e39626. doi:10.1371/journal.pone.0039626
62. Ng, S. K., Neo, S. Y., Yap, Y. W., Karuturi, R. K., Loh, E. S., Liau, K. H., et al. (2009). Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation. Biochem. Biophys. Res. Commun. 387, 310-315.
63. Nobusawa, S., Lachuer, J., Wierinckx, A., Kim, Y. H., Huang, J., Legras, C., et al. (2010). Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol. 20, 936-944.
64. Okkenhaug, K., and Vanhaesebroeck, B. (2003). PI3K-signalling in B-and T-cells: insights from gene-targeted mice. Biochem. Soc. Trans. 31, 270-274.
65. Pallis, A. G., Fennell, D. A., Szutowicz, E., Leighl, N. B., Greillier, L., and Dziadziuszko, R. (2011). Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br. J. Cancer 105, 1-8.
66. Peyton, J. D., Rodon Ahnert, J., Burris, H., Britten, C., Chen, L. C., Tabernero, J., et al. (2011). A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J. Clin. Oncol. 29, abstr. 3066. [ASCO Annual Meeting Proceedings].
67. Rao, S. K., Edwards, J., Joshi, A. D., Siu, I. M., and Riggins, G. J. (2010). A survey of glioblastoma genomic amplifications and deletions. J. Neurooncol. 96, 169-179.
68. Roper, J., Richardson, M. P., Wang, W. V., Richard, L. G., Chen, W., Coffee, E. M., et al. (2011). The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS ONE 6:e25132. doi:10.1371/journal.pone.0025132
69. Salkeni, M. A., Beg, M. S., Olowokure, O. O., Fathallah, H., Thomas, H., Mercer, C. A., et al. (2012). A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme. J. Clin. Oncol. 30, TPS3116. [ASCO Annual Meeting Proceedings].
70. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554.
71. Schepeler, T., Holm, A., Halvey, P., Nordentoft, I., Lamy, P., Riising, E. M., et al. (2012). Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene 31, 2750-2760.
72. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022-8030.
73. Sharma, S. V., and Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231.
74. Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C., and Kern, W. (2004). Adult acute myeloid leukaemia. Crit. Rev. Oncol. Hematol. 50, 197-222.
75. Steelman, L. S., Navolanic, P. M., Sokolosky, M. L., Taylor, J. R., Lehmann, B. D., Chappell, W. H., et al. (2008). Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27, 4086-4095.
76. Stern, H. M. (2012). Improving treatment of HER2-positive cancers: opportunities and challenges. Sci. Transl. Med. 4, 127rv2.
77. Sujobert, P., Bardet, V., Cornillet-Lefebvre, P., Hayflick, J. S., Prie, N., Verdier, F., et al. (2005). Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066.
78. Turner, S. J., Domin, J., Waterfield, M. D., Ward, S. G., and Westwick, J. (1998). The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. J. Biol. Chem. 273, 25987-25995.
79. Vadas, O., Burke, J. E., Zhang, X., Berndt, A., and Williams, R. L. (2011). Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 4, re2.
80. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341.
81. Virbasius, J. V., Guilherme, A., and Czech, M. P. (1996). Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J. Biol. Chem. 271, 13304-13307.
82. Vogelstein, B., and Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nat. Med. 10, 789-799.
83. Von Hoff, D. D., Lorusso, P., Demetri, G. D., Weiss, G. J., Shapiro, G., Ramanathan, R. K., et al. (2011). A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 29, 3052. [ASCO Annual Meeting Proceedings].
84. Wagner, A. J., Von Hoff, D. H., Lorusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., et al. (2009). A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. 27, abstr. 3501. [ASCO Annual Meeting Proceedings].
85. Wallin, J. J., Guan, J., Prior, W. W., Lee, L. B., Berry, L., Belmont, L. D., et al. (2012). GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin. Cancer Res. 18, 3901-3911.
86. Weigelt, B., and Downward, J. (2012). Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol. 2:109. doi:10.3389/fonc.2012.00109
87. Weinstein, I. B. (2000). Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21, 857-864.
88. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.
89. Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L., and Alfred Yung, W. K. (2012). Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-oncology 14, 819-829.
90. Yao, E., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham-Anderson, J., et al. (2009). Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res. 15, 4147-4156.
91. Yoshioka, K., Yoshida, K., Cui, H., Wakayama, T., Takuwa, N., Okamoto, Y., et al. (2012). Endothelial PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat. Med. 18, 1560-1569.
92. Yu, W., Sun, X., Tang, H., Tao, Y., and Dai, Z. (2010). Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells. Leuk. Lymphoma 51, 1098-1107.
93. Zheng, J., Zou, X., and Yao, J. (2012). The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells. Chemotherapy 58, 273-281.
94. Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., et al. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U.S.A. 104, 16158-16163.
95. Zou, Z. Q., Zhang, L. N., Wang, F., Bellenger, J., Shen, Y. Z., and Zhang, X. H. (2012). The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol. Med. Rep. 5, 503-508.